International Journal of Multidisciplinary Research and Growth Evaluation.

Achieving Personalized Oncology Care: Insights and Challenges in Sub-Saharan Africa

Kayode Ademola Matthew [1*], Frank Nwaogelenya Opia [2], Ayodele Matthew [3], Abiodun Florence Kumolu [4], Temitayo Femi Matthew [5]

[1, 2] Department of Accident and Emergency, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria
[3] Department of Oral and Maxillofacial Pathology and Oral Medicine, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria
[4] Department of Child Dental Health, Faculty of Dentistry, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria
[5] College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria

* Corresponding Author: **Kayode Ademola Matthew**

Article Info

ISSN (online): 2582-7138
Volume: 03
Issue: 01
January-February 2022
Received: 25-01-2022
Accepted: 27-02-2022
Page No: 103-111

Abstract
Personalized oncology care, which involves tailoring cancer treatment to an individual patient's unique genetic, environmental, and lifestyle characteristics, has gained momentum globally as an effective strategy for improving cancer outcomes. However, implementing personalized oncology care in Sub-Saharan Africa presents significant challenges due to resource constraints, limited healthcare infrastructure, and sociocultural diversity. This review explores the insights and challenges surrounding personalized oncology care in the region, highlighting both opportunities and barriers. Key challenges include limited access to advanced diagnostic tools, such as genomic sequencing, which are essential for developing personalized treatment plans. Inadequate healthcare infrastructure and a shortage of trained oncology specialists exacerbate the difficulty of implementing precision medicine. Financial constraints, both at the patient and systemic levels, further limit access to innovative therapies and technologies. Additionally, sociocultural factors, including stigma and lack of awareness about cancer, hinder patient engagement and adherence to treatment. Despite these obstacles, innovative solutions are emerging. Collaborative efforts between governments, non-governmental organizations (NGOs), and international partners are driving advancements in cancer research and care delivery. Investments in telemedicine, mobile health platforms, and regional research initiatives have shown promise in bridging gaps in access and knowledge. Furthermore, localized cancer registries and biobanks are providing critical data to inform context-specific approaches to treatment. To achieve sustainable personalized oncology care in Sub-Saharan Africa, strategic investments in healthcare infrastructure, capacity building, and partnerships are essential. Addressing disparities in access to diagnostics and treatments, while fostering community engagement, will be critical for improving cancer outcomes in this resource-constrained region. This review underscores the urgent need for coordinated efforts to make personalized oncology care a reality in Sub-Saharan Africa.

DOI: https://doi.org/10.54660/.IJMRGE.2022.3.1.775-783

Keywords: Oncology care, Challenges, Sub-Saharan, Africa

1. Introduction

One of the main causes of death worldwide is still cancer, and its prevalence is rising in Sub-Saharan Africa, where healthcare systems deal with particular difficulties (Ayandipo *et al*., 2020). A revolutionary approach to cancer management is personalized oncology care, which customizes cancer diagnosis, treatment, and care for each patient according to lifestyle, environmental, leverages advancements in genomics, molecular biology, and data analytics to deliver precise interventions that maximiz

efficacy while minimizing adverse effects. In the context of Sub-Saharan Africa, the relevance of personalized oncology care cannot be overstated. The region faces a growing cancer burden driven by population growth, aging, urbanization, and changing lifestyles (Gyasi and Phillips, 2020). According to the International Agency for Research on Cancer (IARC), cancer cases in Sub-Saharan Africa are projected to nearly double by 2040, with breast, cervical, and prostate cancers being the most prevalent. This alarming trend places immense pressure on already strained healthcare systems, characterized by limited resources, inadequate infrastructure, and a critical shortage of oncology specialists. Moreover, the genetic diversity within African populations, combined with unique environmental exposures and sociocultural factors, underscores the importance of context-specific strategies for cancer prevention, diagnosis, and treatment (Epe *et al*., 2018; Mandell *et al*., 2019). Personalized oncology care presents both opportunities and challenges in Sub-Saharan Africa (Boyle *et al*., 2019). While it has the potential to transform cancer care by improving therapeutic outcomes, lowering treatment-related toxicities, and improving diagnostic accuracy, there are also significant barriers that need to be addressed, such as limited access to advanced diagnostic technologies like genomic sequencing, inadequate funding for healthcare, and disparities in access to care. Additionally, sociocultural factors, such as the stigma associated with cancer and socioeconomic disparities in health literacy, pose additional barriers to the adoption of personalized oncology (Pashayan *et al*., 2020). This explores the insights, challenges, and opportunities associated with implementing personalized oncology care in Sub-Saharan Africa. By examining innovative approaches and lessons learned from regional and global initiatives, this review aims to provide a comprehensive understanding of how personalized oncology can be adapted to resource-constrained settings (Rahman *et al*., 2019; Kundrod *et al*., 2019). Key areas of focus include building infrastructure for genomic and molecular diagnostics, strengthening healthcare capacity through workforce training, and fostering partnerships between governments, non-governmental organizations, and international stakeholders.

As Sub-Saharan Africa grapples with an escalating cancer crisis, the adoption of personalized oncology care could serve as a critical lever for improving outcomes. However, this requires sustained investments, innovative solutions, and coordinated efforts to overcome systemic barriers. By addressing the unique realities of the region, personalized oncology can play a pivotal role in reducing the cancer burden and advancing equitable healthcare for all (Gill *et al*., 2020). This underscores the urgency of prioritizing cancer care innovations in Sub-Saharan Africa to ensure that the promise of personalized medicine becomes a reality for those who need it most.

2. The need for personalized oncology care in sub-Saharan Africa

The growing cancer burden in Sub-Saharan Africa underscores the urgent need for tailored strategies to address its unique challenges. Personalized oncology care, which involves tailoring cancer prevention, diagnosis, and treatment to the specific needs of individual patients, is an emerging approach that offers significant promise for improving cancer outcomes in the region (Yurkovich *et al*., 2020; Tsimberidou *et al*., 2020). By accounting for genetic, environmental, and sociocultural factors, personalized oncology provides an opportunity to overcome the limitations of conventional, one-size-fits-all approaches to cancer care.

The International Agency for Research on Cancer (IARC) predicts that by 2040, the number of cancer cases in Sub-Saharan Africa will nearly double, with cervical, breast, and prostate cancers accounting for the majority of the region's cancer cases. For example, cervical cancer is still the most common cancer among women in the region, primarily due to ongoing infections with high-risk HPV types and limited access to screening and vaccination programs. Breast cancer, which is frequently diagnosed at advanced stages due to inadequate healthcare infrastructure, accounts for a significant portion of cancer-related mortality among women (Mutebi *et al*., 2020). Similarly, prostate cancer is a leading cancer among men, with African populations showing higher rates of aggressive disease compared to other regions. This growing burden places immense pressure on healthcare systems that are already stretched thin. Delayed diagnosis, limited access to advanced diagnostic tools, and a shortage of oncology specialists exacerbate the challenges. The high prevalence of advanced-stage cancers highlights the need for targeted prevention and treatment strategies that address the specific realities of Sub-Saharan Africa.

The genetic diversity of African populations is among the highest in the world, presenting both opportunities and challenges for cancer care. Genetic variations can influence cancer susceptibility, progression, and response to treatment (Valle *et al*., 2019). For example, studies have shown that certain genetic polymorphisms prevalent in African populations may affect drug metabolism, impacting the effectiveness and toxicity of commonly used chemotherapy agents. Furthermore, limited representation of African populations in global genomic research has resulted in gaps in understanding how genetic factors contribute to cancer risk and treatment response in the region. Environmental factors further complicate the cancer landscape in Sub-Saharan Africa. Infectious agents play a significant role in cancer etiology, with HPV being the primary cause of cervical cancer and hepatitis B and C viruses contributing to liver cancer (Liardo *et al*., 2021). Additionally, the prevalence of HIV/AIDS in the region increases the risk of virus-associated malignancies such as Kaposi sarcoma and non-Hodgkin lymphoma. Poor access to preventive measures, such as vaccines and early detection programs, exacerbates the impact of these infectious agents. Environmental exposures to carcinogens, including aflatoxins in improperly stored food and pollutants from industrial and agricultural activities, also contribute to cancer risk. The interplay between genetic and environmental factors highlights the need for personalized oncology care that incorporates genomic profiling and local environmental considerations into cancer prevention and treatment strategies (Shui *et al*., 2021; Aristei *et al*., 2021).

The application of global cancer treatment protocols to Sub-Saharan Africa has proven insufficient in addressing the region’s unique challenges. Many existing treatment guidelines are based on clinical trials conducted in high-income countries, where genetic, environmental, and healthcare contexts differ significantly from those in the global south (Wells *et al*., 2021). For instance, chemotherapy regimens that are effective in Western populations may result in higher toxicity in African populations due to genetic differences in drug metabolism. Similarly, radiation therapy protocols designed for well-resourced settings may not be feasible in regions with limited infrastructure and access to trained personnel. In addition to these clinical challenges, the sociocultural context of Sub-Saharan Africa further limits the effectiveness of standardized approaches. Stigma surrounding cancer, low levels of health literacy, and

traditional beliefs about disease often delay treatment-seeking behaviors (Esther *et al*., 2021). Furthermore, healthcare inequities, including urban-rural disparities and socioeconomic barriers, prevent many patients from accessing timely and effective care. Personalized oncology care offers a pathway to overcome these limitations by providing targeted interventions that address the specific needs of individual patients and populations. For instance, integrating genomic profiling into cancer care can improve diagnostic accuracy and inform the selection of therapies with the highest likelihood of success. Additionally, tailoring treatment protocols to the realities of resource-limited settings, such as shortened chemotherapy regimens or low-cost diagnostic tools, can enhance accessibility and affordability (Jacobs *et al*., 2019).

The rising cancer incidence in Sub-Saharan Africa, coupled with the region's unique genetic and environmental factors, highlights the critical need for personalized oncology care. Traditional, one-size-fits-all approaches fail to address the complexities of cancer management in the region, resulting in suboptimal outcomes and widening health disparities (Hekler *et al*., 2020). By leveraging advancements in genomics and molecular biology, personalized oncology has the potential to transform cancer care in Sub-Saharan Africa, improving survival rates and quality of life for millions. However, achieving this requires a concerted effort to build healthcare infrastructure, foster research collaborations, and ensure equitable access to innovative therapies. Prioritizing personalized oncology care is essential for addressing the growing cancer crisis in Sub-Saharan Africa and advancing global health equity.

2.1 Key insights into personalized oncology care

Personalized oncology care represents a transformative approach to cancer management, offering tailored prevention, diagnosis, and treatment strategies based on individual patient characteristics (Penedo *et al*., 2020; Raijada *et al*., 2021). In Sub-Saharan Africa, efforts to implement personalized oncology are gaining momentum, driven by advancements in genomic research, the integration of biomarkers, and emerging technologies such as artificial intelligence and big data analytics. These innovations hold immense potential to address the unique challenges of the region and improve cancer outcomes.

Fig 1: Key insights into personalized oncology care

Genomic research has become a cornerstone of personalized oncology, enabling a deeper understanding of the genetic underpinnings of cancer. In Sub-Saharan Africa, significant strides have been made to map the genomic landscape of cancers that disproportionately affect the region (Murphy *et al*., 2020). Despite being one of the most genetically diverse regions globally, African populations have historically been underrepresented in global genomic studies, limiting insights into how genetic variations influence cancer susceptibility, progression, and treatment responses. Initiatives like the Human Heredity and Health in Africa (H3Africa) program have been pivotal in addressing this gap. Launched in 2010, H3Africa aims to facilitate genomic research across the continent, focusing on diseases with a significant public health impact, including cancer. By fostering collaborations among African scientists, building local research capacity, and promoting data sharing, the program has advanced understanding of the genetic factors contributing to cancers prevalent in the region, such as cervical, breast, and prostate cancers. For instance, genomic studies have identified specific gene mutations and polymorphisms associated with higher cancer risks or poorer treatment outcomes in African populations, highlighting the need for context-specific interventions. The integration of genomic data into cancer care in Sub-Saharan Africa remains in its early stages, but ongoing research efforts hold promise for developing targeted therapies that align with the region's unique genetic profiles (Munung *et al*., 2021; Hamdi *et al*., 2021). These advancements underscore the importance of continued investment in genomic research to support personalized oncology care.

Biomarkers play a critical role in early cancer detection, diagnosis, and treatment customization. These biological molecules, which can be measured in blood, tissues, or other body fluids, provide valuable information about the presence and progression of cancer, as well as the likelihood of treatment response. In personalized oncology, biomarkers enable the stratification of patients into subgroups based on their molecular profiles, allowing for the selection of therapies most likely to be effective (Hu and Dignam, 2019). In Sub-Saharan Africa, the integration of biomarkers into cancer care has shown promising results. For example, testing for HPV DNA is being increasingly utilized for cervical cancer screening, offering greater sensitivity and accuracy compared to traditional Pap smears. Similarly, biomarkers such as HER2 and estrogen receptor (ER) status are routinely used to guide treatment decisions in breast cancer patients, ensuring that targeted therapies like trastuzumab are administered only to those likely to benefit. Despite these advancements, challenges remain in scaling up biomarker testing in resource-limited settings. High costs, inadequate laboratory infrastructure, and a shortage of trained personnel limit access to these technologies for many patients (Greaves *et al*., 2019). Addressing these barriers is crucial to realizing the full potential of biomarker-driven personalized oncology care in Sub-Saharan Africa.

Emerging technologies such as artificial intelligence (AI) and big data analytics are revolutionizing personalized oncology care by enabling more precise and efficient treatment planning. AI algorithms can analyze vast datasets, including genomic, clinical, and imaging data, to identify patterns and predict treatment responses (Bi *et al*., 2019). These insights can be used to develop personalized treatment plans that optimize outcomes while minimizing side effects. In Sub-Saharan Africa, the application of AI and big data in oncology is still in its infancy but shows great potential. For instance, AI-powered diagnostic tools are being explored to address the shortage of pathologists in the region, enabling automated analysis of histopathology slides and improving diagnostic accuracy. Additionally, big data platforms are being developed to integrate patient data from multiple sources, facilitating real-time monitoring and decision-making. By leveraging these technologies, researchers can uncover novel biomarkers, identify drug targets, and develop predictive models tailored to the region's unique cancer landscape (Boniolo *et al*., 2021). While these innovations offer exciting possibilities, their implementation faces significant challenges, including data privacy concerns, limited digital infrastructure, and the need for robust regulatory frameworks. Addressing these issues will be critical to unlocking the potential of emerging technologies in personalized oncology care.

Advancements in genomic research, the integration of biomarkers, and the adoption of emerging technologies have laid the foundation for personalized oncology care in Sub-Saharan Africa. Programs like H3Africa have catalyzed genomic studies in the region, while biomarker-driven approaches have improved the precision of cancer diagnosis and treatment. Emerging technologies such as AI and big data hold the potential to further enhance personalized care by enabling more efficient and accurate decision-making. Despite these developments, significant challenges remain, including limited infrastructure, high costs, and workforce shortages (Jones *et al*., 2019). Overcoming these barriers will require sustained investment, capacity building, and international collaboration. By leveraging these insights and addressing existing gaps, Sub-Saharan Africa can pave the way for more equitable and effective cancer care, ultimately improving outcomes for millions of patients across the region.

2.2 Challenges in Implementing Personalized Oncology Care

Personalized oncology care holds great promise in improving cancer outcomes through tailored interventions based on genetic, environmental, and lifestyle factors. However, implementing this advanced approach in Sub-Saharan Africa is fraught with significant challenges that hinder its widespread adoption. These barriers, spanning infrastructure, workforce, costs, ethics, and research, must be addressed to make personalized oncology care accessible and effective in the region.

One of the major challenges in implementing personalized oncology care is the lack of infrastructure and resources necessary for advanced diagnostics and genomic research. Sub-Saharan Africa faces limited access to genomic sequencing technologies, advanced diagnostic tools, and specialized laboratories required for identifying genetic mutations and biomarkers (Anigilaje and Olutola, 2019). Even in urban centers where these facilities exist, they are often overwhelmed by demand, leading to long wait times and delayed diagnoses. Furthermore, the logistical challenges of transporting samples from rural areas to central labs further exacerbate the situation. Addressing these infrastructure gaps will require significant investment in healthcare systems, partnerships with global organizations, and innovative solutions, such as mobile diagnostic units and point-of-care testing technologies.

Another critical challenge is the shortage of oncologists and specialized healthcare professionals trained in personalized medicine. Sub-Saharan Africa faces a severe lack of healthcare personnel, with an average of less than one oncologist per million people in many countries. This shortage is compounded by the absence of training programs focused on genomic medicine, biomarker analysis, and data interpretation. Without a skilled workforce, the implementation of personalized oncology care remains unattainable. Efforts to address this issue should focus on building local capacity through the establishment of training programs, scholarships for specialized education, and knowledge-sharing initiatives with international experts. Additionally, empowering nurses, community health workers, and general practitioners with basic oncology training can help bridge the gap in rural and underserved areas (Hand *et al*., 2021).



Fig 2: Challenges in implementing personalized oncology care

The high cost of genetic testing and personalized therapies presents another significant barrier. For instance, the cost of a single genomic sequencing test can be several thousand dollars, far beyond the reach of most patients in Sub-Saharan Africa. Personalized therapies, such as targeted drugs and immunotherapies, are similarly expensive, making them inaccessible to those without substantial financial resources. Economic disparities and the lack of comprehensive health insurance coverage further exacerbate this issue (Mein, 2020). In many countries, out-of-pocket payments account for a large portion of healthcare expenses, placing an

immense burden on patients and their families. To address this challenge, governments and stakeholders need to prioritize healthcare financing mechanisms, such as subsidies, public-private partnerships, and the expansion of health insurance schemes. Additionally, advocating for tiered pricing models and collaborations with pharmaceutical companies can help reduce the cost of personalized oncology interventions. Ethical and cultural factors also pose challenges to the adoption of personalized oncology care. Mistrust in medical interventions, particularly those involving genetic testing, is prevalent in some communities (Sutton *et al*., 2019). This mistrust is often rooted in low levels of awareness about personalized medicine and a lack of understanding of its potential benefits. Furthermore, ethical concerns regarding genetic data sharing and privacy are significant. Many patients fear that their genetic information could be misused, leading to stigmatization, discrimination, or breaches of confidentiality. Addressing these concerns requires robust policies and regulations to ensure data security, transparency, and informed consent. Community engagement and education campaigns can also play a crucial role in building trust and promoting the acceptance of personalized oncology care. The lack of large-scale, Africa-specific cancer research is another major obstacle to personalized oncology care in Sub-Saharan Africa. Most cancer studies and clinical trials have historically focused on populations in high-income countries, resulting in a lack of data on the genetic and environmental factors influencing cancer in African populations. This knowledge gap limits the development of tailored interventions and contributes to the reliance on global treatment protocols that may not be effective for local contexts. To overcome this challenge, there is an urgent need to invest in Africa-specific cancer research, including population-based studies and clinical trials. Collaborative efforts between local researchers, governments, and international organizations, such as the Human Heredity and Health in Africa (H3Africa) program, can help generate valuable data and insights (Mboowa *et al*., 2021). The implementation of personalized oncology care in Sub-Saharan Africa faces multifaceted challenges, including infrastructure deficits, workforce shortages, high costs, ethical concerns, and limited research. Addressing these barriers will require a concerted effort from governments, healthcare providers, researchers, and international stakeholders. By investing in infrastructure, training, financing mechanisms, and research, Sub-Saharan Africa can pave the way for equitable access to personalized oncology care, ultimately improving cancer outcomes and reducing the region's growing cancer burden.

2.3 Opportunities for advancing personalized oncology care

Advancing personalized oncology care in Sub-Saharan Africa presents a unique opportunity to tailor cancer treatment and care based on the region's distinct genetic, environmental, and social contexts. While significant challenges exist, various opportunities can catalyze progress. Strengthening local research capacity, leveraging technology and partnerships, promoting policy and funding initiatives, and engaging with communities are critical pathways to realizing the potential of personalized oncology care in the region. Investing in local research capacity is vital for driving personalized oncology care. Establishing regional cancer genomics programs and biobanks offers an opportunity to generate Africa-specific data critical for understanding cancer patterns unique to the region. Such initiatives can provide insights into genetic variations and their implications for cancer predisposition, progression, and treatment response (Malone *et al*., 2020). Biobanks, which store biological samples such as tissue and blood, are essential for genomic studies and biomarker identification. These resources can serve as a foundation for conducting large-scale population-based studies and clinical trials. Programs like the Human Heredity and Health in Africa (H3Africa) have already demonstrated the feasibility of collaborative genomic research on the continent. Expanding these efforts to focus on cancer genomics will enable the development of tailored diagnostic tools and treatment protocols, enhancing the efficacy of interventions in the region.

Global collaborations and partnerships with international organizations, academic institutions, and the private sector are crucial for advancing personalized oncology care. Such partnerships can facilitate access to innovative technologies, including next-generation sequencing platforms, artificial intelligence (AI) tools, and telehealth systems. AI and machine learning algorithms, for example, can analyze complex genomic data to identify potential biomarkers and recommend personalized treatment plans (Xu *et al*., 2019). These technologies, when integrated into healthcare systems, can improve early cancer detection, optimize treatment decisions, and enhance patient outcomes. Additionally, partnerships can provide training opportunities for healthcare professionals, enabling them to acquire skills in genomic medicine and data analysis. Furthermore, collaborations can also address resource constraints by sharing expertise, technology, and financial resources. Initiatives like the African Cancer Coalition, which aims to improve cancer care through knowledge-sharing and standard-setting, exemplify how partnerships can promote personalized oncology care.



Fig 3: Prospects for enhancing tailored oncology treatment

Supportive policies and increased funding are essential for the successful implementation of personalized oncology care. Governments, in collaboration with stakeholders, need to prioritize cancer care within national health agendas. This includes advocating for funding allocations specifically directed toward cancer research, diagnostic infrastructure, and the integration of personalized medicine into clinical practice. Policy frameworks that incentivize public-private partnerships and encourage pharmaceutical companies to invest in the region are also critical (Laverty and Meulien, 2019). For instance, implementing tiered pricing models for genetic testing and personalized therapies can help reduce costs and improve affordability for patients. Additionally, funding initiatives from international organizations, such as the World Health Organization (WHO) and the Global Fund, can support the development of cancer genomics programs, workforce training, and healthcare infrastructure. Creating regulatory guidelines to govern the ethical use of genetic data is another key policy initiative. Transparent and secure data-sharing frameworks will help address concerns about patient privacy and build public trust in personalized oncology care. Community engagement plays a pivotal role in advancing personalized oncology care by raising awareness and addressing cultural barriers. Low levels of awareness about cancer and its treatments often result in late-stage diagnoses and poor outcomes in Sub-Saharan Africa. Educational campaigns can empower communities with knowledge about the benefits of personalized medicine, the importance of early detection, and the value of genomic research. Engaging with community leaders, religious groups, and local organizations can facilitate culturally sensitive discussions about cancer care and dispel myths or misconceptions. This grassroots approach can also foster trust in healthcare systems, encouraging more individuals to participate in genetic testing and clinical trials. Additionally, community engagement efforts should prioritize rural and underserved populations, where cultural beliefs and limited access to healthcare services pose significant barriers. Mobile health units, for example, can serve as platforms for education, diagnosis, and treatment, ensuring that personalized oncology care reaches even the most remote areas (El-Rashidy *et al*., 2021).

The advancement of personalized oncology care in Sub-Saharan Africa hinges on capitalizing on key opportunities, including strengthening local research capacity, leveraging technology and partnerships, promoting supportive policies and funding, and engaging with communities. By addressing the region's unique needs and challenges, these efforts can lay the groundwork for equitable and effective cancer care (Winkfield *et al*., 2021). As governments, healthcare providers, and global organizations collaborate to implement these strategies, the promise of personalized oncology care can become a reality, improving outcomes and transforming lives across Sub-Saharan Africa.

2.4 Case studies and best practices

The implementation of personalized oncology care in Sub-Saharan Africa has gained momentum through several success stories and innovative initiatives. Despite the significant challenges, these case studies offer valuable lessons on how precision medicine and personalized care models can improve cancer outcomes in the region (Qoronfleh *et al*., 2020). In countries like South Africa, Nigeria, and Kenya, initiatives focused on tailoring cancer treatment to individual genetic profiles are yielding positive results and providing insights into what is possible when local context, resources, and global knowledge are effectively integrated. One notable example of personalized cancer care in Sub-Saharan Africa is the precision medicine program for breast cancer in South Africa. The South African government, in collaboration with local and international stakeholders, launched a pilot program to integrate genomic sequencing and biomarker profiling into breast cancer treatment. The initiative aims to identify genetic mutations and molecular subtypes of breast cancer that are prevalent in African populations. By sequencing tumor DNA and identifying specific mutations, oncologists can tailor treatment plans that are more effective for each individual patient, enhancing treatment response and minimizing unnecessary side effects. Another success story comes from Nigeria, where efforts to integrate targeted therapies for lung cancer have shown promising results. Nigerian oncologists have begun to utilize molecular profiling to identify genetic mutations associated with lung cancer in the local population (Okonta *et al*., 2021). This initiative, which is supported by both local and international funding, has enabled the identification of patients who may benefit from therapies targeting specific mutations, such as epidermal growth factor receptor (EGFR) mutations. By providing targeted therapies, patients have experienced improved clinical outcomes and better quality of life. In Kenya, a similar model has been adopted to integrate personalized treatment for cervical cancer, which remains a significant health challenge in the region due to the high prevalence of human papillomavirus (HPV) infections. The introduction of HPV testing and the use of vaccines have allowed for more personalized prevention strategies, while the incorporation of biomarkers in the treatment process has helped clinicians to more accurately identify patients who would benefit from more aggressive treatment options, such as chemoradiation. These success stories highlight several key lessons that can inform the future of personalized oncology care in Sub-Saharan Africa. One important lesson is the significance of local context in designing precision medicine programs. While global standards and guidelines are useful, cancer care in Sub-Saharan Africa requires adaptation to the region's unique epidemiological patterns and genetic profiles. For example, certain genetic mutations associated with cancers like breast and prostate cancer may vary in prevalence among African populations compared to other ethnic groups. Personalized medicine initiatives that consider these genetic differences are more likely to succeed in improving outcomes. Another valuable lesson is the importance of building local capacity and ensuring sustainability. Successful programs in South Africa, Nigeria, and Kenya all involved significant investments in local healthcare infrastructure, including training healthcare professionals and establishing partnerships with global institutions (Kilmarx *et al*., 2019). Furthermore, creating biobanks and genomic databases for African populations has proven essential in advancing personalized oncology care. These databases enable researchers to identify cancer-related genetic variations that are specific to the region, providing more targeted treatment options and improving outcomes for patients. Additionally, public-private partnerships have played a crucial role in overcoming resource constraints and ensuring access to cutting-edge technologies, such as genomic sequencing platforms. For example, collaborations with international pharmaceutical companies, non-governmental organizations (NGOs), and research institutions have helped bridge the gap in the availability of advanced diagnostic tools and targeted therapies. These partnerships have enabled the implementation of

personalized treatment protocols in low-resource settings, where access to technology and expertise is often limited. A key takeaway from these initiatives is the importance of patient and community engagement. Programs that prioritize education and awareness have seen greater success in increasing patient participation in clinical trials and genomic testing. By engaging with local communities and addressing cultural barriers, healthcare providers can foster trust in personalized oncology care, encouraging more patients to seek out treatment and participate in research initiatives.

The success stories from South Africa, Nigeria, and Kenya demonstrate that personalized oncology care can be effectively integrated into Sub-Saharan Africa's healthcare systems. These case studies highlight the importance of local adaptation, building capacity, fostering partnerships, and engaging communities in cancer care. Moving forward, lessons learned from these initiatives can be applied to other countries in the region, contributing to a more personalized, effective, and equitable approach to cancer treatment (Alfano *et al*., 2019). By continuing to invest in research, technology, and infrastructure, Sub-Saharan Africa has the potential to improve cancer outcomes and reduce the cancer burden in the region.

2.5 Future Directions

The future of personalized oncology care in Sub-Saharan Africa holds immense promise, driven by advancements in genomic research, technological innovations, and regional and global collaborations. However, scaling these efforts will require focused strategies to overcome existing challenges and make personalized cancer care accessible to a broader population. By expanding genomic research, reducing the costs of technologies, and fostering multi-stakeholder partnerships, Sub-Saharan Africa can improve cancer treatment outcomes and address the growing cancer burden (Hunter *et al*., 2020). One of the most significant future directions for personalized oncology care in Sub-Saharan Africa is the expansion of genomic research. African populations are underrepresented in global genomic databases, which are predominantly based on data from European and Asian populations. This lack of representation presents a major barrier to developing personalized cancer care strategies that are tailored to the genetic makeup of African populations. To address this, there is a pressing need to establish larger, more diverse genomic databases that include underrepresented African populations. Expanding these databases will enhance the understanding of cancer-related genetic variations specific to African individuals, thereby improving the accuracy of cancer diagnosis, treatment decisions, and patient outcomes. Initiatives like the Human Heredity and Health in Africa (H3Africa) project have made significant strides in advancing genomic research across the continent (Fadlelmola *et al*., 2021). However, continued investment in research infrastructure, biobanks, and genetic sequencing technologies is required to further build capacity for large-scale genomic studies. In addition to improving cancer treatment options, this effort could provide critical insights into the unique genetic factors contributing to cancer susceptibility in Sub-Saharan Africa, informing both preventive and therapeutic strategies.

The high cost of genomic sequencing and personalized treatments remains a significant barrier to the widespread implementation of personalized oncology care in Sub-Saharan Africa. However, there is growing potential for cost reduction through innovations in technology. For example, advancements in next-generation sequencing (NGS) technologies have significantly reduced the cost and time required for genomic analysis, making it more feasible to integrate genomic testing into routine clinical practice. Another promising avenue for reducing costs is the development of point-of-care diagnostic tools that provide faster, cheaper, and more accessible genetic testing. These innovations would enable more equitable access to personalized cancer care, especially in rural and underserved areas where healthcare infrastructure is limited. In addition, the growing availability of generic versions of targeted cancer therapies and immunotherapies could help lower the cost of personalized treatments. As more African pharmaceutical companies engage in the production and distribution of affordable cancer drugs, there will be greater potential for reducing treatment costs and increasing patient access to life-saving therapies (Baxi *et al*., 2019).

A key component of advancing personalized oncology care in Sub-Saharan Africa is building robust regional and global collaborations. By forging partnerships between governments, non-governmental organizations (NGOs), research institutions, and the private sector, Sub-Saharan African countries can pool resources and expertise to drive advancements in cancer care (Klingholz *et al*., 2020). Collaborative efforts can help address issues such as limited access to advanced diagnostic technologies, shortages of healthcare professionals, and the lack of infrastructure for personalized treatment delivery. At the regional level, countries can create shared resources, such as biobanks and research hubs, to facilitate the exchange of knowledge and data on cancer genomics. Regional collaborations could also focus on the development of training programs for healthcare providers, ensuring that oncologists, nurses, and laboratory technicians are equipped with the skills necessary to implement personalized oncology care effectively. On the global stage, multi-stakeholder partnerships can help improve access to cutting-edge technologies and research findings (Okitasari *et al*., 2021). Collaboration with international organizations such as the World Health Organization (WHO), the National Cancer Institute (NCI), and pharmaceutical companies can facilitate the transfer of knowledge, technology, and funding to support the development and implementation of personalized oncology strategies in Sub-Saharan Africa. Moreover, collaborations with global cancer research initiatives, such as the Global Oncology Network, can promote the exchange of data and best practices, driving innovation in cancer care for African populations.

The future of personalized oncology care in Sub-Saharan Africa hinges on scaling genomic research, reducing the costs of genomic technologies and treatments, and fostering regional and global collaborations. By expanding research efforts, embracing technological innovations, and building multi-stakeholder partnerships, Sub-Saharan Africa can address the unique challenges it faces in cancer care and make significant strides toward providing personalized treatment for its growing cancer burden. While challenges remain, the potential for a transformative shift in cancer care through personalized approaches is within reach, paving the way for better outcomes and improved survival rates for cancer patients across the continent (Patrício *et al*., 2020).

3. Conclusion

Personalized oncology care holds significant promise for addressing the rising cancer burden in Sub-Saharan Africa. As cancer incidence increases, particularly in cancers like breast, cervical, and prostate cancer, there is an urgent need to tailor treatments to the unique genetic, environmental, and socio-economic contexts of African populations.

Personalized care, grounded in genomic research and advanced diagnostic tools, allows for more precise, effective treatments and better patient outcomes. However, the challenges ranging from infrastructure limitations to workforce shortages remain formidable, necessitating a concerted effort to overcome these barriers.

Addressing these challenges will require innovation in technology, especially in genomic research and cost-effective diagnostic tools. The expansion of local research capacity, such as regional cancer genomics programs and biobanks, is essential to generating African-specific cancer data that can drive personalized treatment strategies. Additionally, global and regional collaborations can enhance access to the latest technologies and foster knowledge-sharing among countries, ultimately promoting the widespread integration of personalized oncology care.

Collaboration among policymakers, researchers, healthcare providers, and international organizations is crucial in ensuring that personalized cancer care is not just a luxury but an accessible standard of care across Sub-Saharan Africa. It is imperative that governments prioritize the funding and development of policies that support equitable access to personalized oncology services. Furthermore, healthcare providers must be equipped with the necessary skills and resources to implement these advanced care models, particularly in underserved areas.

Ultimately, personalized oncology care has the potential to revolutionize cancer treatment in Sub-Saharan Africa, but it requires sustained innovation, research, and collaboration. By addressing the region's unique challenges, Sub-Saharan Africa can move closer to achieving equitable and effective cancer care for all its citizens.

4. References

1. Agur Z, Elishmereni M, Foryś U, Kogan Y. Accelerating the development of personalized cancer immunotherapy by integrating molecular patients' profiles with dynamic mathematical models. Clin Pharmacol Ther. 2020;108(3):515-527.
2. Alfano CM, Jefford M, Maher J, Birken SA, Mayer DK. Building personalized cancer follow-up care pathways in the United States: lessons learned from implementation in England, Northern Ireland, and Australia. Am Soc Clin Oncol Educ Book. 2019;39:625-639.
3. Anigilaje EA, Olutola A. Prospects of genetic testing for steroid-resistant nephrotic syndrome in Nigerian children: a narrative review of challenges and opportunities. Int J Nephrol Renovasc Dis. 2019;12:119-136.
4. Aristei C, Perrucci E, Alì E, Marazzi F, Masiello V, Saldi S, *et al*. Personalization in modern radiation oncology: methods, results and pitfalls. Personalized interventions and breast cancer. Front Oncol. 2021;11:616042.
5. Ayandipo O, Wone I, Kenu E, Fasehun LK, Ayandipo O, Gaye F, *et al*. Cancer ecosystem assessment in West Africa: health systems gaps to prevent and control cancers in three countries: Ghana, Nigeria, and Senegal. Pan Afr Med J. 2020;35(1).
6. Baxi SM, Beall R, Yang J, Mackey TK. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications. Glob Health. 2019;15:1-14.
7. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, *et al*. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. 2019;69(2):127-157.
8. Boniolo F, Dorigatti E, Ohnmacht AJ, Saur D, Schubert B, Menden MP. Artificial intelligence in early drug discovery enabling precision medicine. Expert Opin Drug Discov. 2021;16(9):991-1007.
9. Boyle P, Ngoma T, Sullivan R, Brawley O. Cancer in Africa: the way forward. ecancermedicalscience. 2019;13.
10. El-Rashidy N, El-Sappagh S, Islam SR, El-Bakry HM, Abdelrazek S. Mobile health in remote patient monitoring for chronic diseases: principles, trends, and challenges. Diagnostics (Basel). 2021;11(4):607.
11. Epel ES, Crosswell AD, Mayer SE, Prather AA, Slavich GM, Puterman E, *et al*. More than a feeling: a unified view of stress measurement for population science. Front Neuroendocrinol. 2018;49:146-169.
12. Esther N, Julius S, Deogratius MA. Understanding health-seeking and adherence to treatment by patients with esophageal cancer at the Uganda Cancer Institute: a qualitative study. BMC Health Serv Res. 2021;21:1-14.
13. Fadlelmola FM, Zass L, Chaouch M, Samtal C, Ras V, Kumuthini J, *et al*. Data management plans in the genomics research revolution of Africa: challenges and recommendations. J Biomed Inform. 2021;122:103900.
14. Gill J, Fontrier AM, Miracolo A, Kanavos P. Access to personalised oncology in Europe. London School of Economics. 2020.
15. Greaves RF, Bernardini S, Ferrari M, Fortina P, Gouget B, Gruson D, *et al*. Key questions about the future of laboratory medicine in the next decade of the 21st century: a report from the IFCC-Emerging Technologies Division. Clin Chim Acta. 2019;495:570-589.
16. Gyasi RM, Phillips DR. Aging and the rising burden of noncommunicable diseases in sub-Saharan Africa and other low-and middle-income countries: a call for holistic action. Gerontologist. 2020;60(5):806-811.
17. Hamdi Y, Zass L, Othman H, Radouani F, Allali I, Hanachi M, *et al*. Human OMICs and computational biology research in Africa: current challenges and prospects. OMICS. 2021;25(4):213-233.
18. Hand T, Rosseau NA, Stiles CE, Sheih T, Ghandakly E, Oluwasanu M, *et al*. The global role, impact, and limitations of Community Health Workers (CHWs) in breast cancer screening: a scoping review and recommendations to promote health equity for all. Glob Health Action. 2021;14(1):1883336.
19. Hekler E, Tiro JA, Hunter CM, Nebeker C. Precision health: the role of the social and behavioral sciences in advancing the vision. Ann Behav Med. 2020;54(11):805-826.
20. Hu C, Dignam JJ. Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. JCO Precis Oncol. 2019;1:1-12.
21. Hunter N, Dempsey N, Tbaishat F, Jahanzeb M, Al-Sukhun S, Gralow JR. Resource-stratified guideline-based cancer care should be a priority: Historical context and examples of success. Am Soc Clin Oncol Educ Book. 2020;40:217-226.
22. Jacobs J, Hardy L, Semret M, Lunguya O, Phe T, Affolabi D, Yansouni C, Vandenberg O. Diagnostic bacteriology in district hospitals in sub-Saharan Africa: at the forefront of the containment of antimicrobial resistance. Front Med (Lausanne). 2019;6:205.
23. Jones A, Rahman RJ, Jiaqing O. A crisis in the countryside: Barriers to nurse recruitment and retention in rural areas of high-income countries: A qualitative meta-analysis. J Rural Stud. 2019;72:153-163.
24. Kilmarx PH, Katz F, Razak MH, Palen J, Cheever LW,

Glass RI. The medical education partnership initiative: Strengthening human resources to end AIDS and improve health in Africa. Acad Med. 2019;94(11):1704-1713.
25. Klingholz R, Sütterlin S, Kaps A, Hinz C. Leapfrogging Africa: Sustainable Innovation in Health, Education and Agriculture. African Sun Media; 2020.
26. Kundrod KA, Smith CA, Hunt B, Schwarz RA, Schmeler K, Richards-Kortum R. Advances in technologies for cervical cancer detection in low-resource settings. Expert Rev Mol Diagn. 2019;19(8):695-714.
27. Kyomuhendo C, Adeola R. Green and grey: Nutritional lifestyle and healthful ageing in rural and urban areas of three Sub-Saharan African countries. Bus Strat Dev. 2021;4(1):22-33.
28. Laverty H, Meulien P. The innovative medicines initiative − 10 years of public-private collaboration. Front Med (Lausanne). 2019;6:275.
29. Liardo RLE, Borzì AM, Spatola C, Martino B, Privitera G, Basile F, *et al*. Effects of infections on the pathogenesis of cancer. Indian J Med Res. 2021;153(4):431-445.
30. Malone ER, Oliva M, Sabatini PJ, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12:1-19.
31. Mandell R, Israel BA, Schulz AJ. Breaking free from siloes: Intersectionality as a collective action frame to address toxic exposures and reproductive health. Soc Mov Stud. 2019;18(3):346-363.
32. Mboowa G, Sserwadda I, Aruhomukama D. Genomics and bioinformatics capacity in Africa: No continent is left behind. Genome. 2021;64(5):503-513.
33. Mein SA. COVID-19 and health disparities: The reality of "the Great Equalizer." J Gen Intern Med. 2020;35(8):2439-2440.
34. Munung NS, Ambele MA, Moela P. Advancing global equity in cancer genomics–challenges and opportunities in Sub-Saharan Africa. Curr Opin Genet Dev. 2021;66:20-24.
35. Murphy AB, Jordan-Bychkov TG, Jordan BB. The European Culture Area: A Systematic Geography. Rowman & Littlefield Publishers; 2020.
36. Mutebi M, Anderson BO, Duggan C, Adebamowo C, Agarwal G, Ali Z, *et al*. Breast cancer treatment: A phased approach to implementation. Cancer. 2020;126:2365-2378.
37. Okitasari M, Prabowo MH, Santono H. Multi-stakeholder partnerships: A tangible instrument to support the implementation of the 2030 agenda at the local level. Soc Dev Issues. 2021;42(3):61-86.
38. Okonta KE, Echieh PC, Abubakar U, Baiyewu LA, Nzewi OC. Management of lung cancer in Africa: Underdiagnosis and poor access to treatment–A close look at Nigeria and West African Sub-region. J Pan Afr Thorac Soc. 2021;2(3):122-129.
39. Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, *et al*. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol. 2020;17(11):687-705.
40. Patrício L, Sangiorgi D, Mahr D, Čaić M, Kalantari S, Sundar S. Leveraging service design for healthcare transformation: Toward people-centered, integrated, and technology-enabled healthcare systems. J Serv Manag. 2020;31(5):889-909.
41. Penedo FJ, Oswald LB, Kronenfeld JP, Garcia SF, Cella D, Yanez B. The increasing value of eHealth in the delivery of patient-centred cancer care. Lancet Oncol. 2020;21(5):e240-e251.
42. Qoronfleh MW, Chouchane L, Mifsud B, Al Emadi M, Ismail S. THE FUTURE OF MEDICINE: Healthcare innovation through precision medicine: Policy case study of Qatar. Life Sci Soc Policy. 2020;16:1-20.
43. Rahman R, Clark MD, Collins Z, Traore F, Dioukhane EM, Thiam H, *et al*. Cervical cancer screening decentralized policy adaptation: An African rural-context-specific systematic literature review. Glob Health Action. 2019;12(1):1587894.
44. Raijada D, Wac K, Greisen E, Rantanen J, Genina N. Integration of personalized drug delivery systems into digital health. Adv Drug Deliv Rev. 2021;176:113857.
45. Shui L, Ren H, Yang X, Li J, Chen Z, Yi C, *et al*. The era of radiogenomics in precision medicine: An emerging approach to support diagnosis, treatment decisions, and prognostication in oncology. Front Oncol. 2021;10:570465.
46. Sutton AL, He J, Tanner E, Edmonds MC, Henderson A, de Mendoza AH, *et al*. Understanding medical mistrust in Black women at risk of BRCA 1/2 mutations. J Health Dispar Res Pract. 2019;12(3):35.
47. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019.
48. Valle L, Vilar E, Tavtigian SV, Stoffel EM. Genetic predisposition to colorectal cancer: Syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol. 2019;247(5):574-588.
49. Wells JC, Sharma S, Del Paggio JC, Hopman WM, Gyawali B, Mukherji D, *et al*. An analysis of contemporary oncology randomized clinical trials from low/middle-income vs high-income countries. JAMA Oncol. 2021;7(3):379-385.
50. Winkfield KM, Regnante JM, Miller-Sonet E, González ET, Freund KM, Doykos PM. Development of an actionable framework to address cancer care disparities in medically underserved populations in the United States: Expert roundtable recommendations. JCO Oncol Pract. 2021;17(3):e278-e293.
51. Xu J, Yang P, Xue S, Sharma B, Sanchez-Martin M, Wang F, *et al*. Translating cancer genomics into precision medicine with artificial intelligence: Applications, challenges and future perspectives. Hum Genet. 2019;138(2):109-124.
52. Yurkovich JT, Tian Q, Price ND, Hood L. A systems approach to clinical oncology uses deep phenotyping to deliver personalized care. Nat Rev Clin Oncol. 2020;17(3):183-194.